Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 67 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Urgency Frequency Clear all

Conditions: Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions: Replens and coconut oil; Combination Product
Lead sponsor: Alta Bates Summit Medical Center; Other
Eligibility: Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Overactive Bladder
Interventions: (VERV™ System), Sham version of (VERV™ System); Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 14
States / cities: Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more

Conditions: Urgency Frequency, Urinary Urge Incontinence
Interventions: InterStim Therapy at rate 5.2 Hz, InterStim Therapy at rate 14 Hz, InterStim Therapy; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Overactive Bladder
Interventions: Tolterodine ER, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 109
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more

Conditions: Urge Incontinence, Urinary Retention
Interventions: Device Medtronic InterStim Tined Leads Models 3889 and 3093; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 16 Years and older
Enrollment: 153 participants
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Los Angeles, California • Minneapolis, Minnesota

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urgency-frequency Syndrome, Urinary Incontinence, Urinary Incontinence, Urge
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 40 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
Interventions: URG101, Placebo; Drug
Lead sponsor: Urigen; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Glendora, California • San Diego, California • Cartersville, Georgia + 1 more

Conditions: Prostatitis, Cystitis, Interstitial, Urinary Bladder, Overactive, Chronic Pelvic Pain Syndrome, Painful Bladder Syndrome
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 3 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Interventions: Axonics SNM System; Device
Lead sponsor: Axonics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 20 more

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Interventions: Lidocaine 2% without vessel constrictor; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Year and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions: fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Urinary Incontinence
Interventions: Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material; Drug · Behavioral
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 51
States / cities: Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 48 more

Conditions: Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions: GW679769; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Long Beach, California • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Overactive Bladder
Interventions: Toviaz, Premarin, Placebo cream; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 30 Years to 100 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Chronic Prostatitis (CP), Chronic Pelvic Pain Syndrome (CPPS), Painful Bladder Syndrome (PBS), Benign Frequency Syndrome (BFS), Interstitial Cystitis
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
Interventions: Not listed
Lead sponsor: Axonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Little Rock, Arkansas • Irvine, California • Redwood City, California + 21 more

Conditions: Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Pulsed Electromagnetic Field (PEMF) Therapy; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Overactive Bladder (OAB)
Interventions: Detrol LA; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 11
States / cities: Anaheim, California • La Mesa, California • Aurora, Colorado + 8 more

Conditions: Urinary Frequency/Urgency, Bladder Irritable, Bladder Pain Syndrome
Interventions: Mirabegron; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 89 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Incontinence, Urinary Frequency/Urgency, Urinary Bladder, Overactive
Interventions: OnabotulinumtoxinA 100Unit Injection; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Overactive Bladder, Urgency-frequency Syndrome
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Miami, Florida

Conditions: Interstitial Cystitis
Interventions: MN-001 BID, MN-001, Placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 28
States / cities: Birmingham, Alabama • Glendora, California • Long Beach, California + 25 more

Search by objective public record fields.

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

InterStim Therapy Programming Study

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control

rTMS in Overactive Bladder

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

Linkage Analysis in Interstitial Cystitis

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

Identifying Genetic Causes of IC/BPS

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

Premarin Versus Toviaz for Treatment of Overactive Bladder

Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Axonics SacRal NeuromodulaTIon System RegisTRY Study

PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome

Detrol LA In Men With Overactive Bladder.

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

OnabotulinumtoxinA Bladder Injection Study

OAB and the Microbiome

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis